Roche and Defand enter molecular glue discovery collaboration targeting cancer and immune-mediated diseases

The FDA has approved Pfizer's Tukysa in combination with trastuzumab and pertuzumab as a first-line maintenance treatment for adults with HER2-positive advanced breast cancer.

Orion Pharma and Qilu Pharma Europe have entered a European commercialisation agreement for a proposed intravenous pembrolizumab biosimilar.

GE HealthCare has agreed to acquire SOFIE Biosciences for $945 million, expanding its US PET radiopharmaceutical manufacturing and distribution network.

The FDA has moved Jaypirca into first-line CLL and SLL treatment following Phase III data showing a substantial reduction in the risk of disease progression or death.

STADA and SBP Group have launched a strategic biosimilars partnership beginning with a proposed Keytruda biosimilar and providing a framework for up to three additional programmes.

Merck has secured exclusive worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing transaction worth up to $2.13 billion.

The FDA has approved Teva's DEGEVMA as a biosimilar to Xgeva across all reference-product indications, expanding competition in denosumab treatment.

The FDA has approved Lyrfigtu for adults with previously treated FGFR2-altered cholangiocarcinoma, adding a new targeted therapy for this molecularly defined group of bile duct cancers.

The FDA has granted final approval to Lantheus' Bravnetsa for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours.

Boehringer Ingelheim and Envisagenics have entered a multi-year oncology collaboration worth more than $1 billion to discover therapeutic targets created by alternative RNA splicing.

Novartis has secured exclusive worldwide rights to an undisclosed preclinical radioligand therapy from BoomRay Pharma in a licensing agreement worth up to $900 million.

AbbVie and Iambic have entered a multi-year collaboration to use artificial intelligence and computational drug discovery across immunology, neuroscience and oncology.

Grünenthal has agreed to acquire Bayer's established oncology medicine Stivarga in a transaction worth up to €375 million.

The FDA has approved Inluriyo in combination with Verzenio for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following progression on endocrine therapy.

Telix Pharmaceuticals has agreed to acquire ITM in a major radiopharmaceutical transaction valued at $1.65 billion upfront, with up to a further $700 million linked to regulatory and commercial milestones.

Escugen Biotechnology and Sovran Biosciences have expanded their oncology collaboration with a co-development agreement for a pan-tumour bispecific antibody-drug conjugate.

The FDA has approved shorter monitoring requirements following the first two doses of Amgen's Imdelltra, reducing observation time from 22–24 hours to 6–8 hours.

The FDA has expanded the approved use of Ameluz with red-light photodynamic therapy to include treatment of superficial basal cell carcinoma in adults.

The FDA has approved Curium's Bexlutry as the first radioligand equivalent to Lutathera for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours.